A novel role for Reelin therapeutics in inflammatory bowel disease
Reelin 疗法在炎症性肠病中的新作用
基本信息
- 批准号:10079713
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AminosalicylateAnti-Inflammatory AgentsAntibodiesApolipoproteinsAttenuatedAutopsyBindingBinding ProteinsBiologicalBiological ModelsBiological ProductsBloodBody Weight decreasedCellsChronicCicatrixClinical TrialsColitisColonCrohn&aposs diseaseDegenerative DisorderDisease ProgressionDisease modelDisease remissionDrug TargetingE-SelectinEndothelial CellsExcisionExtracellular Matrix ProteinsExtravasationFecesFlareFlow CytometryGenesGeneticGoalsHistologicInfiltrationInflammationInflammatoryInflammatory Bowel DiseasesInflammatory InfiltrateIntegrinsIntercellular adhesion molecule 1IntestinesJanus kinaseLaboratoriesLengthLeukocyte Adhesion MoleculesMeasuresMedicalMethotrexateModelingMolecularMonitorMonoclonal AntibodiesMusMutationOperative Surgical ProceduresPathologyPatientsPatternPenetrancePharmaceutical PreparationsPlasmaPlasma ProteinsPredispositionReceptor CellRelapseRiskRoleSeveritiesSeverity of illnessSignal TransductionSiteSodium Dextran SulfateSystemTNF geneTestingTherapeuticTissuesUlcerative ColitisUnited StatesVascular Cell Adhesion Molecule-1apolipoprotein E receptor 2basechronic ulcercytokinedrinking waterdysbiosisefficacy testingexperienceexperimental studygut microbiomehuman modelinhibiting antibodyintestinal epitheliumintestinal injurymouse modelmucosal addressin cell adhesion molecule-1neutralizing antibodynovelnovel therapeuticspre-clinicalpreventreceptorrecruitresponsetargeted agenttargeted treatmenttrafficking
项目摘要
Abstract
Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely
understood. Although specific genetic factors may increase risk, most IBD cannot be readily
explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated.
Once IBD is established, chronic inflammation is a central hallmark and also a major target for
therapy. Both forms of IBD, Crohn’s Disease (CD) and Ulcerative Colitis (UC), are typically
characterized by periods of remission and flares. The flares can be serious and difficult to
reverse, contributing to irreversible tissue damage. Existing therapies for IBD are insufficient
and identification of new targets represents an important goal. We have identified a novel system
that controls inflammation. Reelin, a plasma protein, binds to endothelial cell ApoER2,
increasing expression of diverse endothelial cell receptors involved in transporting inflammatory
cells into regions of inflammation. The major goal of this proposal is to test our hypothesis that
targeting the Reelin/ApoER2 system therapeutically may be efficacious in IBD. In preliminary
studies, we have shown that we can deplete the plasma of Reelin in a stable manner using anti-
Reelin monoclonal antibodies. We also have available mice in which Reelin is deleted. In
Specific Aim 1, we will test the hypothesis that Reelin deletion will decrease the severity of colitis
that develops in response to dextran sodium sulfate (DSS). In Aim 2, we will test the efficacy of
anti-Reelin antibody at attenuating the response to DSS. These proof of principle experiments
will provide pre-clinical evidence in support of our goal to target the Reelin/ApoER2 system
therapeutically in clinical trials in IBD patients.
摘要
导致炎症性肠病(IBD)发病的因素仍不完全
明白了。虽然特定的遗传因素可能会增加风险,但大多数IBD并不容易
基于遗传学的解释。肠道微生物群的失调也有牵连。
一旦IBD确定,慢性炎症是一个中心标志,也是一个主要的治疗目标
心理治疗。两种形式的IBD,克罗恩病(CD)和溃疡性结肠炎(UC),都是典型的
以缓解期和耀斑为特征。耀斑可能是严重的,很难
反之,造成不可逆的组织损伤。现有的治疗IBD的方法还不够
识别新的目标代表着一个重要的目标。我们发现了一种新的系统
它能控制炎症。Reelin是一种血浆蛋白,与内皮细胞ApoER2结合,
参与炎症转导的多种内皮细胞受体表达增加
细胞进入炎症区域。这项提议的主要目标是检验我们的假设
靶向Reelin/ApoER2系统治疗IBD可能是有效的。在预赛中
研究表明,我们可以稳定地耗尽Reelin的血浆。
Reelin单抗。我们也有可以删除Reelin的可用的小鼠。在……里面
具体目标1,我们将检验Reelin缺失将降低结肠炎严重程度的假设
这是对葡聚糖硫酸钠(DSS)的反应。在目标2中,我们将测试
抗Reelin抗体可减弱对DSS的反应。这些原理实验的证明
将提供临床前证据支持我们针对Reelin/ApoER2系统的目标
IBD患者的临床治疗试验中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN L. GONIAS其他文献
STEVEN L. GONIAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN L. GONIAS', 18)}}的其他基金
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
- 批准号:
10358335 - 财政年份:2017
- 资助金额:
$ 40万 - 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
- 批准号:
9913997 - 财政年份:2017
- 资助金额:
$ 40万 - 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
- 批准号:
10557130 - 财政年份:2017
- 资助金额:
$ 40万 - 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
- 批准号:
9285496 - 财政年份:2017
- 资助金额:
$ 40万 - 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
- 批准号:
10693590 - 财政年份:2017
- 资助金额:
$ 40万 - 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
- 批准号:
8613477 - 财政年份:2013
- 资助金额:
$ 40万 - 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
- 批准号:
8501950 - 财政年份:2013
- 资助金额:
$ 40万 - 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
- 批准号:
9023503 - 财政年份:2013
- 资助金额:
$ 40万 - 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
- 批准号:
9215655 - 财政年份:2013
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 40万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 40万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 40万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 40万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 40万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 40万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 40万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 40万 - 项目类别: